Margy Meislin

Positive Data at EADV Shows Investigational Drug Litifilimab For Cutaneous Lupus Show Durable Symptom Control 

|

The Lupus Research Alliance is encouraged by positive 52-week Phase 2 data (ongoing Phase 2/3 AMETHYST Study) with litifilimab, an investigational drug in development by Biogen. The data presented today at the 2026 EADV Congress in Vienna, Austria further supports its potential to achieve rapid and durable improvements in skin disease activity in adults with cutaneous lupus erythematosus.   “People living with cutaneous … Positive Data at EADV Shows Investigational Drug Litifilimab For Cutaneous Lupus Show Durable Symptom Control 

Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson & Johnson showing significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE). These data, part of the JASMINE study, were presented today at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.  In the JASMINE study, at 52 weeks, nipocalimab plus standard of … Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

Positive Results of Phase 3 Dapirolizumab Pegol Trial in Systemic Lupus Erythematosus Shown in Published Paper

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, welcomes additional positive results from the Phase 3 PHOENYCS GO study showing that combined with standard care, investigational dapirolizumab pegol (DZP) in development by UCB and Biogen Inc. significantly improved disease activity in patients with moderate-to-severe active systemic lupus erythematosus (SLE). These data were published in The Lancet, a highly prestigious … Positive Results of Phase 3 Dapirolizumab Pegol Trial in Systemic Lupus Erythematosus Shown in Published Paper

Saphnelo™ Approved as Self-Administered Autoinjector

|

The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.  The decision was based on TULIP-SC Phase 3 trial results, which showed a statistically significant and clinically meaningful reduction in disease activity for participants with moderate to severe … Saphnelo™ Approved as Self-Administered Autoinjector

Lupus & Life: Heart Health, Lupus, and How You Can Take Control

|

How does lupus impact heart health?  People living with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular disease, with even greater risk among those with lupus nephritis. Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, convened leading rheumatologists and people living with lupus for the first in our webinar series, “Lupus & Life: Science, Support, and Self-Care,” to take a closer look at … Lupus & Life: Heart Health, Lupus, and How You Can Take Control

New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the investigational litifilimab in development by Biogen significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE). These data were presented at the American Academy of Dermatology Annual Meeting on … New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

|

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.  More than 75% of people treated with Gazyva plus standard therapy achieved at least … New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

|

Today, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, announced the expansion of its proven peer-to-peer clinical research education program – Patient Advocates for Lupus Studies (PALS) – making it available to hundreds of individuals living with lupus across North America. The expansion builds on the program’s success to date and aims to … Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

|

The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from Genentech for the treatment of adults with active lupus nephritis in combination with standard of care. This is a major step forward for the entire lupus community, as it is the only anti-CD20 monoclonal antibody targeting an … Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

|
Breaking News

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the … Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study